Corvex Total Equity increased by 16680.4% to $576.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17710.9%, from $3.23M to $576.00M. Over 5 years (FY 2020 to FY 2025), Total Equity shows an upward trend with a -38.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase generally signals growth in retained earnings or capital injections, while a decrease may indicate share buybacks, dividend payments, or net losses.
This represents the residual interest in the assets of the entity after deducting all its liabilities. It reflects the n...
Standard across all public companies; peers in the medical device and diagnostics sector typically maintain high equity levels to support R&D and M&A.
total_stockholders_equity| Q4 '21 | Q1 '22 | Q2 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $32.73M | $26.53M | $20.50M | $7.92M | $11.14M | $12.83M | $4.94M | $3.45M | -$1.48M | $16.78M | $10.25M | $7.36M | $3.23M | $1.64M | -$1.70M | -$3.47M | $576.00M |
| QoQ Change | — | -18.9% | -22.8% | -61.4% | +40.8% | +15.1% | -61.5% | -30.2% | -142.9% | >999% | -38.9% | -28.3% | -56.0% | -49.4% | -203.9% | -104.2% | >999% |
| YoY Change | — | — | — | -75.8% | -58.0% | -37.4% | — | -56.4% | -113.3% | +30.8% | +107.3% | +113.3% | +318.8% | -90.2% | -116.6% | -147.2% | >999% |